|
|
 |
|
Viewing report
|
|
|
|
sanofi-aventis - Pipeline - Products - Performance - Potential
Espicom Business Intelligence Ltd, Sep 2009, Pages: 212
sanofi-aventis was formed in August 2004, when Sanofi-Synthélabo acquired control of Aventis. Subsequently, on 31st December 2004, Aventis merged with and into sanofi-aventis, with sanofi-aventis as the surviving company. With total revenues of over EUR 27 billion in 2008, the combined entity ranks fourth amongst research-based pharmaceutical companies behind Pfizer, GlaxoSmithKline and Novartis.
sanofi-aventis is focused on two core areas, pharmaceuticals (principally prescription drugs) and human vaccines. Within the pharmaceutical area, sanofi-aventis is active in the following therapeutic areas: Cardiovascular/Thrombosis, Metabolism, Oncology, Central Nervous System and Internal Medicine (which includes Respiratory/Allergy, Urology, Arthritis/Osteoporosis and Anti-infectives).
The company has a strong position in Europe, particularly the key markets of Germany, France and Italy. In addition, the acquisition of a shareholding in Zentiva in March 2006, reaffirms sanofi-aventis' commitment to emerging Eastern European markets. The acquisition of Aventis in August 2004, also significantly strengthened Sanofi-Synthélabo's position in the US. Aventis also brought with it a significant presence in Latin America.
Of sanofi-aventis' top 15 products, just two recorded strong double-digit growth in 2008 (compared with six in 2006), three recorded moderate single-digit growth (between 5 and 10 per cent) and two recorded low single digit growth. Five products showed a significant decline in sales of more than 10 per cent; Copaxone, Ambien/Myslee/Stilnox, Delix/Tritace, Eloxatin and Nasacort in particular, were hit particularly hard by intense generic competition and the transfer of marketing rights. A further three, Amaryl, Xatral and Allegra also showed single digit declines.
Sanofi Pasteur has the ability to exploit the expanding influenza market and has key agreements with governments to develop and supply vaccine against H5N1 avian influenza and H1N1 'swine' influenza, in the event of a pandemic being declared, once the actual virus strain responsible is identified.
sanofi-aventis has a particularly strong and broad R&D pipeline, particularly in the metabolism/diabetes area. This, together with the potential for further growth in vaccines, means the outlook for sanofi-aventis for the next few years looks very good.
This new strategic analysis report sanofi-aventis: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
Customers who bought this item also bought
Sanofi-Aventis Partnering Guide 2008
Sanofi- Aventis Medical Equipment Company Share Analysis 2008
Sanofi-Aventis: PharmaVitae Profile
PharmaVitae 2004: Sanofi-Aventis Global & US Analysis
Sanofi-Aventis
Pharmavitae 2005: Sanofi-Aventis Global Analysis
Pharmavitae 2005: Sanofi-Aventis Global And US Analysis
sanofi-aventis IMS Company Profile
Sanofi-Aventis: PharmaVitae Model
Sanofi-Aventis: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
PharmaVitae 2004: Sanofi-Aventis Global Analysis
Sanofi-Aventis - Financial and Strategic Analysis Review
|
|
|
|
